Item no. |
EP07959_1 |
Manufacturer |
peptides & elephants
|
Amount |
1 mg |
Category |
|
Type |
Peptides |
Specific against |
other |
ECLASS 10.1 |
32160409 |
ECLASS 11.0 |
32160409 |
UNSPSC |
12352202 |
Alias |
FLYALALLL Latent membrane protein HLA-A*02:01 Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Nasopharyngeal carcinoma T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
Available |
|
Description |
Antigen Peptide EBV LMP2 HLA-A*0201 (FLYALALLL) for stimulation of human EBV LMP2(356-364)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. LYALALLL is a linear peptidic epitope studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). |
Keywords |
FLYALALLL Latent membrane protein HLA-A*02:01 Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Nasopharyngeal carcinoma T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
Sequence |
FLYALALLL |
N-Terminus |
H |
C-Terminus |
NH2 |
Purity |
0, 95 |
Counter-Ion |
TFA |
Protein |
Latent membrane protein |
Gene |
LMP2 |
Allele |
HLA-A*02:01 |
Application |
T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
Indication |
Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Nasopharyngeal carcinoma |
Storage |
Store dry at -20°C |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.